Human stem cells institute PJSC

What Human stem cells institute PJSC does

Artgen Biotech is a Russian publicly traded biotechnology company (Moscow Exchange ticker ABIO, founded 2003) that operates as a holding structure for an ecosystem of biotech subsidiaries at varying stages of development, from seed to maturity. The group is organized around three product verticals: (1) Preparations — biomedical products including vaccines, antibodies, and gene therapy preparations; (2) Medical Products — medical devices based on gene-activated materials for regenerative medicine and test systems for medical genetics; and (3) Medical Services — biobanking, genetic research, and cell-based regenerative medicine services. The company describes its core capability as "platform technologies" that enable the creation of new drugs in innovative biomedicine directions, supported by an internal patent portfolio and three identified operating subsidiaries: Gemabank (Гемабанк) for cord blood and stem cell storage, Genetico for genetic research and tumor testing, and РБТ for organ preservation solutions.

The company serves Russian healthcare institutions with advanced biomedical products, regenerative medicine treatments, and genetic diagnostics. Its go-to-market operates through subsidiaries and partnerships with major Russian medical research centers (e.g., Almazov National Medical Research Centre for organ preservation), distributing via B2B channels into the healthcare sector. Specific pricing models, customer logos, revenue figures, and headcount are not disclosed in available source material; the company maintains BBB-(RU) credit rating confirmed by ACRA on 06.07.2026. Geographic footprint is concentrated in Russia with no disclosed international expansion, and the company is listed on the Moscow Exchange with formal investor relations infrastructure including e-disclosure (Interfax-CRKI) and Tinkoff Pulse channels. The business model appears to combine product sales (biomedical preparations and medical devices) with service revenue (biobanking, genetic testing) and ecosystem acceleration activities.

Name

Human stem cells institute PJSC

Legal name

Artgen Biotech (Артген биотех)

Website

https://hsci.ru

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Artgen Biotech is a Russian publicly traded biotechnology holding company (Moscow Exchange: ABIO) operating an ecosystem of subsidiaries developing biomedical preparations, gene-activated medical devices, and cell-based regenerative medicine services for the Russian healthcare sector.

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Biomedical preparations
• Regenerative medicine
• Gene therapy products
• Medical genetic testing
• Biobanking services

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Marketing channels4 records

Core offering

Artgen Biotech develops and commercializes biomedical preparations (vaccines, antibodies, gene therapy products), medical devices based on gene-activated materials for regenerative medicine, and medical genetic test systems. It also delivers medical services including biobanking, genetic research, and cell-based regenerative medicine therapies through its subsidiaries Gemabank, Genetico, and RBT.

Product overview

Artgen Biotech is a diversified biotechnology company with a portfolio of innovative platform technologies organized into three core product areas: (1) Preparations — biomedical products including vaccines, antibodies, and gene therapy drugs; (2) Medical Products — gene-activated materials for regenerative medicine and medical genetics test systems; (3) Medical Services — biobanking, genetic testing, and cell-based regenerative medicine services. The company operates as an ecosystem of companies at various stages from seed to maturity, developing technologies for improving healthcare effectiveness and medical care quality.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomedical Preparations (vaccines, antibodies, gene therapy products) Development of biomedical preparations including vaccines, antibodies, gene therapy preparations and other biological products for medical applications. Targeted at healthcare institutions and medical facilities requiring advanced therapeutics.
• Medical Devices (gene-activated materials and genetic test systems) Development and implementation of medical devices based on gene-activated materials in regenerative medicine, and test systems for medical genetics. Aimed at clinical practitioners and medical institutions.
• Medical Services (biobanking, genetic research, regenerative medicine) Biobanking, genetic research for medical and scientific purposes, and services in regenerative medicine based on cell technologies. Available to patients, healthcare providers, and research institutions.
• Gemabank Cord Blood and Stem Cell Storage Services Subsidiary service offering cord blood and stem cell storage for medical and personal use. Operated through wholly-owned subsidiary Гемabank (Gemabank).
• Genetico Genetic Research and Tumor Testing Genetic research and tumor testing products and services. Operated through wholly-owned subsidiary Genetico. New tumor research product launched July 2026.
• RBT Organ Preservation Solutions Organ preservation solutions for donor organs. Operated through wholly-owned subsidiary RBT. First domestic Russian organ preservation solution being brought to market in partnership with Almazov Centre (announced June 2026).

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• bluebird bio: Gene therapy company developing lentiviral-based treatments for genetic diseases and oncology. Comparable as a gene therapy platform with proprietary gene delivery technology, though broader in indication scope.
• Pharmstandard: One of Russia's largest pharmaceutical manufacturers producing a broad portfolio of branded and generic medicines. Comparable as a Russian domestic pharmaceutical producer benefiting from import-substitution, though Artgen is more focused on biotech and regenerative medicine.
• Vertex Pharmaceuticals: Global biotechnology company with significant investments in cell and gene therapies (including the acquired ViaCyte program for type 1 diabetes). Comparable as a large-cap biotech with strategic exposure to cell-based regenerative therapies, though operating at vastly larger scale.

Emerging players

• Gamida Cell: Cell therapy company developing omidubicel (allogeneic stem cell therapy) for blood cancers and other indications. Comparable as an allogeneic cell therapy developer serving hematology and broader regenerative medicine applications.
• ViaCyte: Cell therapy developer focused on stem cell-derived therapies for type 1 diabetes, acquired by Vertex Pharmaceuticals. Comparable as a developer of stem cell-based regenerative therapies using proprietary differentiation platforms.

Direct peers

• Mesoblast: Australian cell therapy company developing allogeneic cellular medicines for inflammatory diseases, heart failure, and musculoskeletal conditions. Comparable as a regenerative medicine / cell therapy platform targeting similar indications to Artgen's gene-activated and cell-based therapies.
• Pluristem Therapeutics: Israel-based cell therapy company using placenta-derived adherent stromal cells for regenerative medicine applications. Comparable as a developer of cell-based regenerative therapies targeting musculoskeletal and inflammatory indications.
• Cord Blood Registry (CBR): Largest private newborn stem cell bank in the world, storing cord blood and cord tissue stem cells. Comparable as a cord blood stem cell banking service provider with operational scale similar to Artgen's Gemabank subsidiary.
• BIOCAD: Leading Russian biotechnology company developing biosimilars, monoclonal antibodies, and gene therapy products. Comparable as a domestic Russian biotech platform with diversified pipeline across biologics and innovative therapeutics serving Russian healthcare.
• Generium: Russian biotechnology company focused on biological products including recombinant proteins, monoclonal antibodies, and cell/gene therapies. Comparable as a Russia-based innovator in biomedical preparations and biologics manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/hsci_russia
• Facebookfacebook.com/hscirussia
• LinkedInlinkedin.com/company/human-stem-cells-institute

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human stem cells institute PJSC